Enobia Pharma
www.enobia.comEnobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposphostasia.
Read more
Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposphostasia.
Read more
Country
City (Headquarters)
Montréal
Industry
Employees
11-50
Estimated Revenue
$1,000,000 to $5,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Marketing Officer
Email ****** @****.comPhone (***) ****-****Senior Clinical Study Manager
Email ****** @****.comPhone (***) ****-****Consultant
Email ****** @****.comPhone (***) ****-****
Technologies
(8)
Reach decision makers at Enobia Pharma
Free credits every month!
Enobia Pharma FAQ
Montréal, Canada
Biotechnology Research
